Literature DB >> 12740491

Association of E-cadherin gene 3'-UTR C/T polymorphism with calcium oxalate stone disease.

Fuu-Jen Tsai1, Hsi-Chin Wu, Huey-Yi Chen, Hsueh-Fu Lu, Cheng-Der Hsu, Wen-Chi Chen.   

Abstract

INTRODUCTION: Urinary stone disease is one of the most commonly seen urological diseases in Taiwan. Single nucleotide polymorphisms (SNPs) are commonly used for the investigation of genetic markers for stone disease. E-cadherin (CDH-1) is one of the cellular junction proteins related to the integrity of epithelial cells. Our aim was to investigate a polymorphism of the CDH-1 gene 3'-UTR as a possible genetic marker in the search for the genetic causes.
MATERIALS AND METHODS: 148 patients with calcium oxalate stone were compared with 103 healthy controls for the frequency of CDH-1 3'-UTR polymorphisms. The polymorphism was detected by polymerase chain reaction-based restriction analysis (PML I endonuclease). RESULTS AND
CONCLUSIONS: The results revealed significant differences between normal individuals and calcium stone disease patients (p = 0.0013). The distribution of genotype TT homozygote was higher in stone patients (51.5%) than in the control group (43.4%). The odds ratio for T allele compared to C allele was 2.0. We have concluded that polymorphisms of CDH-1 3'-UTR is a valid genetic marker for calcium stone disease. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12740491     DOI: 10.1159/000070135

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  9 in total

1.  Update on the genetics of nephrolithiasis.

Authors:  Giuseppe Vezzoli; Teresa Arcidiacono; Vera Paloschi; Annalisa Terranegra; Rita Biasion; Laura Soldati
Journal:  Clin Cases Miner Bone Metab       Date:  2008-05

Review 2.  A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants.

Authors:  Jian-Min Chen; Claude Férec; David N Cooper
Journal:  Hum Genet       Date:  2006-06-29       Impact factor: 4.132

3.  E-cadherin gene 3'-UTR C/T polymorphism in Turkish patients with nephrolithiasis.

Authors:  Akin Yilmaz; Sevda Menevse; Metin Onaran; Ilker Sen; Mehmet Ali Ergun; Ahmet Camtosun; Bora Kupeli; Ibrahim Bozkirli
Journal:  Mol Biol Rep       Date:  2010-12-14       Impact factor: 2.316

4.  E-cadherin polymorphisms and breast cancer susceptibility: a report from the Shanghai Breast Cancer Study.

Authors:  Alicia Beeghly-Fadiel; Wei Lu; Yu-Tang Gao; Jirong Long; Sandra L Deming; Qiuyin Cai; Ying Zheng; Xiao-ou Shu; Wei Zheng
Journal:  Breast Cancer Res Treat       Date:  2009-10-16       Impact factor: 4.872

5.  Predisposition of genetic polymorphism with the risk of urolithiasis.

Authors:  Rama D Mittal; Hemant K Bid; Parmeet K Manchanda; Rakesh Kapoor
Journal:  Indian J Clin Biochem       Date:  2008-06-11

6.  Genetic polymorphisms as prognostic factors for recurrent kidney stones: A systematic review and meta-analysis.

Authors:  Widi Atmoko; Putu Angga Risky Raharja; Ponco Birowo; Agus Rizal Ardy Hariandy Hamid; Akmal Taher; Nur Rasyid
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

7.  The -160C>a polymorphism in E-cadherin is associated with the risk of nephrolithiasis.

Authors:  Mingyue Tan; Shengqiang Xia; Qi Zhang; Jiang Zhu; Erdun Bao
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

8.  Might E-cadherin promoter polymorphisms of rs16260 and rs5030625 associate with the risk of nephrolithiasis?

Authors:  Cigdem Donmez; Ece Konac; Batuhan T Aydogan; Cenk Y Bilen
Journal:  Springerplus       Date:  2016-09-29

9.  A whole genome SNP genotyping by DNA microarray and candidate gene association study for kidney stone disease.

Authors:  Nanyawan Rungroj; Choochai Nettuwakul; Nirinya Sudtachat; Oranud Praditsap; Nunghathai Sawasdee; Suchai Sritippayawan; Duangporn Chuawattana; Pa-Thai Yenchitsomanus
Journal:  BMC Med Genet       Date:  2014-05-02       Impact factor: 2.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.